Sofy Landes, MD
Cardiovascular Disease · Ladson, SCNPI 1265790133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,432 and has fallen 77.7% since, to $320 in 2025.
Across 271 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$839
- E.r. Squibb & Sons, L.L.C.$518
- Boehringer Ingelheim$428
- AstraZeneca$402
- Medtronic$319
- Heartflow, Inc.$285
- plus $2K from 26 others
Across 5 payments — averaging $4564.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$23K
What the payments were for
- Food & beverage$5,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $839 |
| E.r. Squibb & Sons, L.L.C. | 35 | $518 |
| Boehringer Ingelheim | 24 | $428 |
| AstraZeneca | 28 | $402 |
| Medtronic(2 entities) | 16 | $319 |
| Heartflow, Inc. | 4 | $285 |
| Merck | 18 | $279 |
| Amgen | 15 | $264 |
| Inari Medical, Inc. | 1 | $252 |
| Novartis | 15 | $247 |
| Pfizer | 16 | $237 |
| Boston Scientific | 8 | $170 |
| Abbott | 7 | $119 |
| Philips North America LLC | 5 | $108 |
| Sanofi-aventis U.S. LLC | 5 | $101 |
| Irhythm Technologies, Inc. | 3 | $89 |
| Alnylam Pharmaceuticals Inc. | 4 | $84 |
| Scpharmaceuticals Inc. | 4 | $81 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| United Therapeutics Corporation | 2 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $45 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Teleflex LLC | 1 | $44 |
| Biotronik Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Cvrx, Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$415
- FLOWTRIEVER CATHETER, S$252
- CT THROMBECTOMY SYSTEM KIT$252
- FFRct$135
How this compares
$5,278 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 210 | $212,253 |
| EntrestoSacubitril/Valsartan | 89 | $124,067 |
| JardianceEmpagliflozin | 43 | $51,472 |
| XareltoRivaroxaban | 37 | $33,564 |
| FarxigaDapagliflozin Propanediol | 23 | $29,051 |
| Repatha SureclickEvolocumab | 23 | $18,021 |
| Atorvastatin Calcium | 192 | $2,022 |
| Carvedilol | 168 | $1,745 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 11 | $1,682 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 114 | $1,674 |
| Metoprolol Succinate | 118 | $1,600 |
| Spironolactone | 169 | $1,385 |
| Losartan Potassium | 134 | $1,222 |
| Furosemide | 261 | $1,168 |
| Flecainide Acetate | 25 | $1,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $237 | $212,253210 claims |
| NovartisEntresto | $247 | $124,06789 claims |
| Boehringer IngelheimJardiance | $428 | $51,47243 claims |
| Johnson & JohnsonXarelto | $839 | $33,56437 claims |
| AstraZenecaFarxiga | $402 | $29,05123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Ladson
- Christopher McCartyLadson$13K
- Frederick FunkeLadson$11K
- Jason CokerLadson$10K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.